Lantern Pharma Inc. (LTRN)
Lantern Pharma Inc. (LTRN) Stock Price, Analysis & Data
| Bid | 2.01 |
| Market Cap | 34.58M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -15.91M |
| Beta | 2.33 |
| EPS (ttm) | -1.45 |
| PE Ratio (ttm) | n/a |
| Forward PE | -1.34 |
| P/B (ttm) | 8.86 |
| P/S (ttm) | n/a |
| Earnings Date | Aug 14, 2026 |
| Ask | 3.46 |
| Volume | 94,317 |
| Avg. Volume (20D) | 206,977 |
| Open | 2.83 |
| Previous Close | 2.78 |
| Day's Range | 2.63 - 2.83 |
| 52-Week Range | 1.11 - 4.86 |
| Analyst | Strong Buy |
| Price Target | 17.5 (545.76%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About LTRN
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1a clinical trial for the treatment of advanced or metastatic solid tumors, or unresectable or recurrent GBM, solid tumor, such as pancreatic, breast, bladder, and lung canc...
Financial Performance
In 2025, Lantern Pharma's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -17.12M, a decrease of -17.62%.
Financial StatementsAnalyst Forecast
According to 2 analyst ratings, the average rating for LTRN stock is "Strong Buy". The 12-month stock price forecast is 17.5, which is upside of 545.76% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
